Affibody appoints Peter Zerhouni as CFO
Solna, Sweden, October 3, 2023. Affibody AB (“Affibody”) today announced that Peter Zerhouni has been appointed Chief Financial Officer (CFO) of the Company.
Peter Zerhouni joined Affibody as Chief Business Officer (CBO) in April of 2023. He will combine the roles of CFO and CBO.
“Since joining Affibody, I have been thoroughly impressed with my colleagues’ expertise and the potential of the product pipeline. I am excited to contribute to our strategic growth initiatives and taking the Company to the next level,” said Peter Zerhouni, CFO and CBO of Affibody.
Peter Zerhouni has vast experience from leading positions in biopharmaceutical companies. As CEO of InDex Pharmaceuticals he was responsible for taking the company public and raising more than USD 100 million in financings. He also led the clinical development of InDex’s lead asset through Phase 2 and into Phase 3, as well as preparing for commercialization and launch. Prior to this he was with Diamyd Medical, both as President and CEO and Director of Business Development. During his time at Diamyd he was responsible for leading the business development efforts that led to a USD 625 million partnership with Johnson & Johnson. Earlier in his career he worked at the global financial institution ING Group.
Peter Zerhouni holds an MSc in Biology and a BSc in Business Administration and Economics from Lund University, and he has also studied at University of California at Berkeley.
About Affibody
________________________________________
Affibody is a clinical stage integrated biopharmaceutical company with a broad product pipeline focused on developing innovative bi- and multi-specific next generation biopharmaceutical drugs based on its unique proprietary technology platform, Affibody® molecules. Through its validated business model, the company has a proven capability of identifying and prioritizing strategic projects in a timely and de-risked way. Affibody has established several partnerships for the development and commercialization of its innovations with international pharmaceutical companies. Affibody’s main shareholder Patricia Industries is a part of Investor AB.
Further information can be found at: www.affibody.com
Disclaimer
________________________________________
This press release contains forward-looking statements. While Affibody consider the projections to be based on reasonable assumptions, these forward-looking statements may be called into question by several hazards and uncertainties, so that actual results may differ materially from those anticipated in such forward-looking statements.
Contacts
________________________________________
Affibody
David Bejker, CEO, +46 706 454 948
Peter Zerhouni, CFO and CBO, +46 706 420 044
Affibody Media Contact
Richard Hayhurst/Ola Björkman, RHA Communications, +44 7711 821 527, richard@rhacomms.eu
